The Asia Pacific T-Cell therapy Market would witness market growth of 18.5% CAGR during the forecast period (2023-2030).
T-cell-based methods are widely used in the discipline of cancer immunotherapy now due to their higher success rate. The expanding field of gene therapy has a significant impact on the efficacy of CAR T therapies. The growing investment will probably lead to further expansion of the gene therapy sector. However, because of CAR T-cell therapy, some cancer cells can be made by scientists to be more easily found and eliminated by T-cells. The requirement for CAR T-cell therapy will therefore be driven in the near future by the predicted rise in cancer patients.
Although HICs have higher overall rates of cancer incidence, LMICs have much higher death rates and total cancer-related mortality rates, which are also continuing to grow, compared to HICs, where mortality rates are either falling or remaining stable. Hence, the acceptance of T-cell therapies is anticipated to be fueled in the coming years by increased manufacturer promotional efforts and a rise in public knowledge of effective cancer treatment pharmaceuticals.
The most frequent type of leukemia in children is acute lymphoblastic leukemia. There have been improvements in treating this disease, and research is ongoing to produce even better results. Like the West, India is seeing an increase in the percentage of ALL cured children. Numerous Indian research has suggested that patients have more high-risk factors. Despite the lack of information regarding cytogenetics in India, a higher percentage of children have unfavorable cytogenetics. Since the region has many children, the demand for T-cell therapies is anticipated to increase. For example, according to a recent projection by the United Nations International Children's Emergency Fund, India approximately had 444 million children (aged 0 to 18) in 2022. Hence, all these factors are promoting the growth of the regional market.
The China market dominated the Asia Pacific T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $683.9 million by 2030. The Japan market is exhibiting a CAGR of 17.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 19.3% during (2023 - 2030).
Based on End User, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide T-Cell therapy Market is Projected to reach USD 9.2 Billion by 2030, at a CAGR of 17.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific T-Cell therapy Market, by End User
1.4.2 Asia Pacific T-Cell therapy Market, by Indication
1.4.3 Asia Pacific T-Cell therapy Market, by Therapy Type
1.4.4 Asia Pacific T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. Asia Pacific T-Cell therapy Market by End User
4.1 Asia Pacific Hospitals Market by Country
4.2 Asia Pacific Cancer Treatment Centers Market by Country
Chapter 5. Asia Pacific T-Cell therapy Market by Indication
5.1 Asia Pacific Lymphoma Market by Country
5.2 Asia Pacific Acute Lymphocytic Leukemia Market by Country
5.3 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific T-Cell therapy Market by Therapy Type
6.1 Asia Pacific CAR T-Cell Therapy Market by Country
6.2 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 Asia Pacific Axicabtagene Ciloleucel Market by Country
6.2.2 Asia Pacific Tisagenlecleucel Market by Country
6.2.3 Asia Pacific Brexucabtagene Autoleucel Market by Country
6.2.4 Asia Pacific Others Market by Country
6.3 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. Asia Pacific T-Cell therapy Market by Country
7.1 China T-Cell therapy Market
7.1.1 China T-Cell therapy Market by End User
7.1.2 China T-Cell therapy Market by Indication
7.1.3 China T-Cell therapy Market by Therapy Type
7.1.3.1 China T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 Japan T-Cell therapy Market
7.2.1 Japan T-Cell therapy Market by End User
7.2.2 Japan T-Cell therapy Market by Indication
7.2.3 Japan T-Cell therapy Market by Therapy Type
7.2.3.1 Japan T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 India T-Cell therapy Market
7.3.1 India T-Cell therapy Market by End User
7.3.2 India T-Cell therapy Market by Indication
7.3.3 India T-Cell therapy Market by Therapy Type
7.3.3.1 India T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 South Korea T-Cell therapy Market
7.4.1 South Korea T-Cell therapy Market by End User
7.4.2 South Korea T-Cell therapy Market by Indication
7.4.3 South Korea T-Cell therapy Market by Therapy Type
7.4.3.1 South Korea T-Cell therapy Market by CAR T-Cell Therapy Type
7.5 Singapore T-Cell therapy Market
7.5.1 Singapore T-Cell therapy Market by End User
7.5.2 Singapore T-Cell therapy Market by Indication
7.5.3 Singapore T-Cell therapy Market by Therapy Type
7.5.3.1 Singapore T-Cell therapy Market by CAR T-Cell Therapy Type
7.6 Malaysia T-Cell therapy Market
7.6.1 Malaysia T-Cell therapy Market by End User
7.6.2 Malaysia T-Cell therapy Market by Indication
7.6.3 Malaysia T-Cell therapy Market by Therapy Type
7.6.3.1 Malaysia T-Cell therapy Market by CAR T-Cell Therapy Type
7.7 Rest of Asia Pacific T-Cell therapy Market
7.7.1 Rest of Asia Pacific T-Cell therapy Market by End User
7.7.2 Rest of Asia Pacific T-Cell therapy Market by Indication
7.7.3 Rest of Asia Pacific T-Cell therapy Market by Therapy Type
7.7.3.1 Rest of Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
TABLE 1 Asia Pacific T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– T-Cell therapy Market
TABLE 4 Product Launches And Product Expansions– T-Cell therapy Market
TABLE 5 Acquisition and Mergers– T-Cell therapy Market
TABLE 6 Geographical Expansions – T-Cell therapy Market
TABLE 7 Trials and Approvals – T-Cell therapy Market
TABLE 8 Asia Pacific T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 9 Asia Pacific T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 10 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 11 Asia Pacific Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 12 Asia Pacific Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
TABLE 13 Asia Pacific Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
TABLE 14 Asia Pacific T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 15 Asia Pacific T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 16 Asia Pacific Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 17 Asia Pacific Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 18 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 19 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
TABLE 20 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 21 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 22 Asia Pacific T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 23 Asia Pacific T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 24 Asia Pacific CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
TABLE 25 Asia Pacific CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
TABLE 26 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 27 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 28 Asia Pacific Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
TABLE 29 Asia Pacific Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
TABLE 30 Asia Pacific Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
TABLE 31 Asia Pacific Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
TABLE 32 Asia Pacific Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
TABLE 33 Asia Pacific Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
TABLE 34 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 35 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 36 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
TABLE 37 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
TABLE 38 Asia Pacific T-Cell therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 Asia Pacific T-Cell therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 China T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 41 China T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 42 China T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 43 China T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 44 China T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 45 China T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 46 China T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 47 China T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 48 China T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 49 China T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 50 Japan T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 51 Japan T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 52 Japan T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 53 Japan T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 54 Japan T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 55 Japan T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 56 Japan T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 57 Japan T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 58 Japan T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 59 Japan T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 60 India T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 61 India T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 62 India T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 63 India T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 64 India T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 65 India T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 66 India T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 67 India T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 68 India T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 69 India T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 70 South Korea T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 71 South Korea T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 72 South Korea T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 73 South Korea T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 74 South Korea T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 75 South Korea T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 76 South Korea T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 77 South Korea T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 78 South Korea T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 79 South Korea T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 80 Singapore T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 81 Singapore T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 82 Singapore T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 83 Singapore T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 84 Singapore T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 85 Singapore T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 86 Singapore T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 87 Singapore T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 88 Singapore T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 89 Singapore T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 90 Malaysia T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 91 Malaysia T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 92 Malaysia T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 93 Malaysia T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 94 Malaysia T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 95 Malaysia T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 96 Malaysia T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 97 Malaysia T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 98 Malaysia T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 99 Malaysia T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 100 Rest of Asia Pacific T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 101 Rest of Asia Pacific T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 102 Rest of Asia Pacific T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 103 Rest of Asia Pacific T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 104 Rest of Asia Pacific T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 105 Rest of Asia Pacific T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 106 Rest of Asia Pacific T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 107 Rest of Asia Pacific T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 108 Rest of Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 109 Rest of Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 110 key Information – Merck KGaA
TABLE 111 Key information –Johnson & Johnson
TABLE 112 Key information – AbbVie, Inc.
TABLE 113 Key Information – Gilead Sciences, Inc.
TABLE 114 Key Information – Amgen, Inc.
TABLE 115 Key Information – Novartis AG
TABLE 116 Key Information – Sorrento Therapeutics, Inc.
TABLE 117 Key Information – Bristol Myers Squibb Company
TABLE 118 Key Information – Pfizer, Inc.
TABLE 119 Key Information – Immunocore Holdings plc
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
FIG 5 Asia Pacific T-Cell therapy Market share by End User, 2022
FIG 6 Asia Pacific T-Cell therapy Market share by End User, 2030
FIG 7 Asia Pacific T-Cell therapy Market by End User, 2019 - 2030, USD Million
FIG 8 Asia Pacific T-Cell therapy Market share by Indication, 2022
FIG 9 Asia Pacific T-Cell therapy Market share by Indication, 2030
FIG 10 Asia Pacific T-Cell therapy Market by Indication, 2019 - 2030, USD Million
FIG 11 Asia Pacific T-Cell therapy Market share by Therapy Type, 2022
FIG 12 Asia Pacific T-Cell therapy Market share by Therapy Type, 2030
FIG 13 Asia Pacific T-Cell therapy Market by Therapy Type, 2019 - 2030, USD Million
FIG 14 Asia Pacific T-Cell therapy Market share by Country, 2022
FIG 15 Asia Pacific T-Cell therapy Market share by Country, 2030
FIG 16 Asia Pacific T-Cell therapy Market by Country, 2019 - 2030, USD Million
FIG 17 Recent strategies and developments: Merck KGaA
FIG 18 Recent strategies and developments: Johnson & Johnson
FIG 19 SWOT analysis: Johnson & Johnson
FIG 20 Recent strategies and developments: Gilead Sciences, Inc.
FIG 21 Recent strategies and developments: Amgen, Inc.
FIG 22 Recent strategies and developments: Novartis AG
FIG 23 Recent strategies and developments: Sorrento Therapeutics, Inc.
FIG 24 Recent strategies and developments: Bristol Myers Squibb Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Recent strategies and developments: Immunocore Holdings plc